Imidacloprid + Moxidectin

Verify with FDA CVM →

18,782 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
18,782
Total Reports
753
Deaths Reported
400.0%
Death Rate

Active Ingredients

ImidaclopridImidacloprid + MoxidectinMoxidectin

Administration Routes

TopicalUnknownOralOtherOphthalmicRespiratory (Inhalation)SubcutaneousTransdermalAuricular (Otic)Cutaneous

Species Affected

Dog 10,582
Cat 6,400
Unknown 1,347
Human 378
Rabbit 36
Ferret 19
Cockatiel 7
Wolf 6
Leopard 2
Mouse 2

Most Affected Breeds

Domestic Shorthair 3,794
Unknown 1,789
Retriever - Labrador 996
Cat (unknown) 927
Crossbred Canine/dog 680
Dog (unknown) 627
Chihuahua 603
Domestic Longhair 596
Terrier - Yorkshire 568
Shih Tzu 457

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 2,397
Pruritus 2,282
Lack of efficacy (ectoparasite) - flea 2,253
Behavioural disorder NOS 1,768
Vomiting 1,503
Hypersalivation 1,096
Diarrhoea 1,027
Anorexia 986
Other abnormal test result NOS 964
Application site alopecia 900
Underfilling, Tubes 787
Ataxia 771

Outcome Breakdown

Outcome Unknown
9,187 (52.7%)
Recovered/Normal
6,881 (39.5%)
Ongoing
577 (3.3%)
Died
460 (2.6%)
Euthanized
293 (1.7%)
Recovered with Sequela
42 (0.2%)

Data Summary

Metric Value
Total adverse event reports 18,782
Reports involving death 753
Case-fatality rate (reported events) 400.0%
Distinct species in reports 10
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 3

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Imidacloprid + Moxidectin Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 18,782 adverse event reports referencing Imidacloprid + Moxidectin, including 753 reports in which the animal died — a 400.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Imidacloprid, Imidacloprid + Moxidectin, Moxidectin. Reported administration routes include Topical, Unknown, Oral, Other. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Imidacloprid + Moxidectin reports are Dog (10,582 reports), Cat (6,400 reports), Unknown (1,347 reports), with Dog accounting for the largest share. Within those species, Domestic Shorthair (3,794), Unknown (1,789), Retriever - Labrador (996) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Imidacloprid + Moxidectin are Lethargy (see also Central nervous system depression in 'Neurological') (2,397), Pruritus (2,282), Lack of efficacy (ectoparasite) - flea (2,253), Behavioural disorder NOS (1,768). Of the 17,440 reports with a coded outcome, Outcome Unknown is the leading category at 52.7%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Imidacloprid + Moxidectin.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial